Literature DB >> 6430224

Inability of purified Pseudomonas aeruginosa exopolysaccharide to bind selected antibiotics.

C S Tannenbaum, A T Hastie, M L Higgins, F Kueppers, G Weinbaum.   

Abstract

It has been proposed that the exopolysaccharide (alginate) of mucoid Pseudomonas aeruginosa strains which infect cystic fibrosis patients might bind and hence protect this pathogen from antibiotics. To test this hypothesis, we employed equilibrium dialysis to measure the binding between several antibiotics and purified Pseudomonas alginate. Binding was calculated from the residual concentrations of antibiotics in free solution by a biological assay. The detectable binding of antibiotics to alginate was consistent with expectations; the positively charged antibiotics steptomycin and tobramycin, bound to the polyanion (0.047 and 0.024 mumol/mg of alginate, respectively), whereas the neutral species, clindamycin and penicillin, bound negligibly or not at all (0.0011 and 0 mumol/mg of alginate, respectively). When these experiments were performed in the presence of physiological concentrations of saline, none of the antibiotics bound to the polysaccharide. Since the binding observed was abrogated by salt concentrations typical of the tracheobronchial secretions of cystic fibrosis patients, the data suggest that tight binding of antibiotics to the exopolysaccharide of a mucoid P. aeruginosa strain does not provide increased antibiotic resistance.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6430224      PMCID: PMC185620          DOI: 10.1128/AAC.25.6.673

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Mucoid Pseudomonas aeruginosa and cystic fibrosis: resistance of the mucoid from to carbenicillin, flucloxacillin and tobramycin and the isolation of mucoid variants in vitro.

Authors:  J R Govan; J A Fyfe
Journal:  J Antimicrob Chemother       Date:  1978-05       Impact factor: 5.790

Review 2.  Cystic fibrosis.

Authors:  R E Wood; T F Boat; C F Doershuk
Journal:  Am Rev Respir Dis       Date:  1976-06

3.  Stoichiometric depolymerization of polyuronides and glycosaminoglycuronans to monosaccharides following reduction of their carbodiimide-activated carboxyl groups.

Authors:  R L Taylor; H E Conrad
Journal:  Biochemistry       Date:  1972-04-11       Impact factor: 3.162

4.  Sensitivity of respiratory strains of Pseudomonas aeruginosa to carbenicillin.

Authors:  J R May; A Ingold
Journal:  J Med Microbiol       Date:  1973-02       Impact factor: 2.472

5.  Uronic acid composition of heparins and heparan sulfates.

Authors:  R L Taylor; J E Shively; H E Conrad; J A Cifonelli
Journal:  Biochemistry       Date:  1973-09-11       Impact factor: 3.162

6.  Antibiotic therapy and cystic fibrosis: increased resistance of mucoid Pseudomonas aeruginosa to carbenicillin.

Authors:  J R Govan
Journal:  J Antimicrob Chemother       Date:  1976-06       Impact factor: 5.790

7.  Mucoid Pseudomonas aeruginosa in patients with chronic illnesses.

Authors:  R G Doggett; G M Harrison; R E Carter
Journal:  Lancet       Date:  1971-01-30       Impact factor: 79.321

8.  Serogroups of Pseudomonas aeruginosa and the immune response of patients with cystic fibrosis.

Authors:  E Diaz; L L Mosovich; E Neter
Journal:  J Infect Dis       Date:  1970-03       Impact factor: 5.226

9.  Incidence of mucoid Pseudomonas aeruginosa from clinical sources.

Authors:  R G Doggett
Journal:  Appl Microbiol       Date:  1969-11

10.  A new polysaccharide resembling alginic acid isolated from pseudomonads.

Authors:  A Linker; R S Jones
Journal:  J Biol Chem       Date:  1966-08-25       Impact factor: 5.157

View more
  8 in total

1.  Modification by surface association of antimicrobial susceptibility of bacterial populations.

Authors:  D G Allison; P Gilbert
Journal:  J Ind Microbiol       Date:  1995-10

2.  Determinants of the efficacy of tobramycin therapy against isogenic nonmucoid and mucoid derivatives of Pseudomonas aeruginosa PAO1 growing in peritoneal chambers in mice.

Authors:  N M Kelly; E G Rawling; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

3.  Inhibition of tobramycin diffusion by binding to alginate.

Authors:  W W Nichols; S M Dorrington; M P Slack; H L Walmsley
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

4.  Agmatine accumulation by Pseudomonas aeruginosa clinical isolates confers antibiotic tolerance and dampens host inflammation.

Authors:  Jennifer L McCurtain; Adam J Gilbertsen; Clayton Evert; Bryan J Williams; Ryan C Hunter
Journal:  J Med Microbiol       Date:  2019-01-22       Impact factor: 2.472

5.  Differential protection from tobramycin by extracellular polymeric substances from Acinetobacter baumannii and Staphylococcus aureus biofilms.

Authors:  Emily K Davenport; Douglas R Call; Haluk Beyenal
Journal:  Antimicrob Agents Chemother       Date:  2014-06-09       Impact factor: 5.191

6.  Pseudomonas aeruginosa biofilm as a diffusion barrier to piperacillin.

Authors:  B D Hoyle; J Alcantara; J W Costerton
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

7.  Characterization of Pseudomonas aeruginosa isolated from chronically infected children with cystic fibrosis in India.

Authors:  Gunjan Agarwal; Arti Kapil; Susheel Kumar Kabra; Bimal Kumar Das; Sada Nand Dwivedi
Journal:  BMC Microbiol       Date:  2005-07-21       Impact factor: 3.605

8.  Diffusion Retardation by Binding of Tobramycin in an Alginate Biofilm Model.

Authors:  Bao Cao; Lars Christophersen; Mette Kolpen; Peter Østrup Jensen; Kim Sneppen; Niels Høiby; Claus Moser; Thomas Sams
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.